Veloxis Pharmaceuticals Presents LCP-Tacro™ Phase 3 Data at the American ... Sacramento Bee LCP-Tacro™ enabled a reduction in dose of 20% through 12 months following a switch from Prograf® as measured by median tacrolimus dose (mg/kg/day) (p<0.00001). Mean tacrolimus trough levels throughout the study were comparable and within the 4-15 ng ... |
